Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

David K. Clarke, Rong Xu, Demetrius Matassov, Theresa Latham, Ayuko Ota‐Setlik, Cheryl Gerardi, Amara Luckay, Susan E. Witko, Luz Hermida, Terry J. Higgins, Marc Adélard Tremblay, Susan Sciotto-Brown, Tracy Chen, Michael A. Egan, Janice M. Rusnak, Lucy Ward, John H. Eldridge